MD1639C2 - ADN sau fragmentele lui ce codifică eritropoietina umană, vectori, celule-gazdă sau linii celulare, ADNc sau fragmentele lui ce codifică eritropoietina umană, eritropoietină recombinantă umană, procedee de obţinere a eritropoietinei umane şi eritropoietinei recombinante umane, compoziţie farmaceutică şi procedeu de obţinere a ei - Google Patents

ADN sau fragmentele lui ce codifică eritropoietina umană, vectori, celule-gazdă sau linii celulare, ADNc sau fragmentele lui ce codifică eritropoietina umană, eritropoietină recombinantă umană, procedee de obţinere a eritropoietinei umane şi eritropoietinei recombinante umane, compoziţie farmaceutică şi procedeu de obţinere a ei

Info

Publication number
MD1639C2
MD1639C2 MD94-0371A MD940371A MD1639C2 MD 1639 C2 MD1639 C2 MD 1639C2 MD 940371 A MD940371 A MD 940371A MD 1639 C2 MD1639 C2 MD 1639C2
Authority
MD
Moldova
Prior art keywords
erythropoietin
human
fragments
recombined
dna
Prior art date
Application number
MD94-0371A
Other languages
English (en)
Russian (ru)
Other versions
MD1639B2 (ro
MD940371A (ro
Inventor
Edward Fritsch
Kenneth Jacobs
Rodney M. Hewick
Original Assignee
Genetics Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27418329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD1639(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SU874203324A external-priority patent/RU1801118C/ru
Application filed by Genetics Institute, Inc. filed Critical Genetics Institute, Inc.
Publication of MD940371A publication Critical patent/MD940371A/ro
Publication of MD1639B2 publication Critical patent/MD1639B2/ro
Publication of MD1639C2 publication Critical patent/MD1639C2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Prezenta invenţie se referă la biotehnologie, industria medico-biologică, medicină şi în special, la ADN clonaţi, care codifică eritropoietina umană, expresiile ADN indicate şi la obţinerea in vitro a eritropoietinei umane active.Se descrie clonarea fragmentelor ADN genom din ficatul fetal uman şi fragmente ale ADNc, care asigură nivele excepţional de înalte ale expresiei eritropoietinei în celulele de mamifere, a fost obţinută linia de celule ovariene de hamster chinezesc CHO, care produce EPO recombinantă (CHO EPO Cla 4a4.02-7). Ca rezultat al expresiei fragmentelor clonate ale ADN în celulele de mamifere s-a obţinut EPO O-glicosilată cu o activitate specifică de cel puţin 200000 unităţi/mg şi compoziţia farmaceutică, în care se utilizează EPO recombinantă menţionată în calitate de ingredient activ.Rezultatul invenţiei constă în creşterea nivelelor de expresie in vitro a eritropoietinei umane active, precum şi în înlăturarea reacţiilor adverse în timpul tratamentului cu eritropoietină recombinantă umană.
MD94-0371A 1984-12-04 1994-07-14 ADN sau fragmentele lui ce codifică eritropoietina umană, vectori, celule-gazdă sau linii celulare, ADNc sau fragmentele lui ce codifică eritropoietina umană, eritropoietină recombinantă umană, procedee de obţinere a eritropoietinei umane şi eritropoietinei recombinante umane, compoziţie farmaceutică şi procedeu de obţinere a ei MD1639C2 (ro)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67781384A 1984-12-04 1984-12-04
US68862285A 1985-01-03 1985-01-03
US69325885A 1985-01-22 1985-01-22
SU874203324A RU1801118C (ru) 1985-01-22 1987-09-09 Способ получени человеческого эритропоэтина

Publications (3)

Publication Number Publication Date
MD940371A MD940371A (ro) 1996-06-28
MD1639B2 MD1639B2 (ro) 2001-03-31
MD1639C2 true MD1639C2 (ro) 2001-10-31

Family

ID=27418329

Family Applications (1)

Application Number Title Priority Date Filing Date
MD94-0371A MD1639C2 (ro) 1984-12-04 1994-07-14 ADN sau fragmentele lui ce codifică eritropoietina umană, vectori, celule-gazdă sau linii celulare, ADNc sau fragmentele lui ce codifică eritropoietina umană, eritropoietină recombinantă umană, procedee de obţinere a eritropoietinei umane şi eritropoietinei recombinante umane, compoziţie farmaceutică şi procedeu de obţinere a ei

Country Status (24)

Country Link
EP (2) EP0205564B2 (ro)
JP (4) JPH0655144B2 (ro)
KR (1) KR890001011B1 (ro)
AT (2) ATE63137T1 (ro)
AU (1) AU621535B2 (ro)
CA (1) CA1341502C (ro)
CZ (3) CZ281756B6 (ro)
DE (3) DE411678T1 (ro)
DK (4) DK172953B1 (ro)
ES (1) ES8800049A1 (ro)
FI (2) FI104261B (ro)
GE (1) GEP19970775B (ro)
GR (1) GR852890B (ro)
HK (2) HK105693A (ro)
HU (1) HU216079B (ro)
IL (1) IL77081A (ro)
LV (2) LV10505B (ro)
MD (1) MD1639C2 (ro)
NO (1) NO304469B1 (ro)
PL (2) PL157926B1 (ro)
PT (1) PT81590B (ro)
SK (2) SK279765B6 (ro)
UA (1) UA44882C2 (ro)
WO (1) WO1986003520A1 (ro)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
DE3789678T2 (de) * 1986-02-27 1994-08-11 Snow Brand Milk Prod Co Ltd Herstellung von erythropoietinproduzierenden Zellen und Verfahren zur Herstellung von Erythropoietin mit Verwendung dieser Zellen.
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
DK175363B1 (da) * 1986-09-12 2004-09-13 Genentech Inc Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
EP0752474A1 (en) * 1995-07-07 1997-01-08 Boehringer Mannheim Gmbh Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
JPH10510434A (ja) * 1995-07-07 1998-10-13 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｍｐ−ｎ−アセチルノイラミン酸ヒドロキシラーゼをコードする核酸及び修飾糖タンパク質の産生のためのその使用
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
NZ337465A (en) 1997-03-18 2002-04-26 Roche Diagnostics Gmbh Pharmaceutical containing erythropoietin and iron preparations for treating haemodialysis patients or anaemias
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
CA2298015C (en) * 1997-07-23 2015-01-27 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
PT986644E (pt) 1997-07-23 2007-01-31 Roche Diagnostics Gmbh Preparação de eritropoietina por activação genética endógena com promotores virais
KR100622203B1 (ko) 1997-07-23 2006-09-07 로셰 디아그노스틱스 게엠베하 내인성 유전자 활성화에 의해 사람 단백질을 생성시키는 사람 세포주를 확인하는 방법
TR200000140T2 (tr) 1997-07-23 2000-05-22 Roche Diagnostics Gmbh Endojenik gen etkinliği ile insan proteini üretimi için insan hücre sıralarının belirlenmesi
DE69726571T2 (de) * 1997-09-01 2004-11-04 Aventis Pharma Deutschland Gmbh Rekombinantes humanes Erythropoietin mit vorteilhaftem Glykosylierungsmuster
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
BR9905868A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
BR9905867A (pt) * 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
BR9917606A (pt) 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
BR0116381A (pt) 2000-12-20 2004-02-25 Hoffmann La Roche Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
KR100505152B1 (ko) * 2001-09-10 2005-08-03 (주)가이아진 아스코르브산을 이용한 에리트로포이에틴의 생산방법
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
ES2297028T3 (es) 2001-12-07 2008-05-01 Crucell Holland B.V. Produccion de virus, aislados virales y vacunas.
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
CA2496317C (en) 2002-09-11 2014-02-18 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EA010650B1 (ru) 2003-09-29 2008-10-30 Уоррен Фармасьютикалз, Инк. Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
DK1699915T3 (da) 2003-12-30 2010-09-13 Augustinus Bader Anvendelse af erythropoietin til levervævsregenerering
DE102004004509B4 (de) 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
EP1732609B1 (en) 2004-03-11 2012-07-11 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein
EP2336192A1 (en) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
GB0507123D0 (en) * 2005-04-08 2005-05-11 Isis Innovation Method
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
AR053416A1 (es) * 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
EP1978030A4 (en) 2006-01-18 2009-12-30 Chugai Pharmaceutical Co Ltd PROCESS FOR REMOVING SIALIC ACID AND METHOD FOR PRODUCING ASIALOERYTHROPOIETIN
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
EP1991569A4 (en) * 2006-03-07 2009-12-23 Regenetech Inc MAMMALIAN BIOLOGICAL MOLECULES WITH NATURAL GLYCOSYLATION PRODUCED BY ELECTROMAGNETIC STIMULATION OF LIVING MAMMALIAN CELLS
WO2007108505A1 (ja) 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha エリスロポエチン溶液製剤
JP5723528B2 (ja) 2006-08-04 2015-05-27 プロロング ファーマシューティカルズ エルエルシー 修飾されたエリスロポエチン
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2095829A1 (en) 2008-02-27 2009-09-02 LEK Pharmaceuticals D.D. Selenium containing modifying agents and conjugates
DE102008002210A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur fermentativen Herstellung von Erythropoietin
DE102008002209A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur Aufreinigung von Erythropoietin
EP2334699B1 (en) 2008-09-23 2013-09-11 F. Hoffmann-La Roche AG Purification of erythropoietin
DE102008054716A1 (de) 2008-12-16 2010-06-17 Evonik Degussa Gmbh Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
MX2012003558A (es) 2009-09-23 2012-07-03 Biogenerix Ag Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden.
WO2017068051A1 (en) 2015-10-21 2017-04-27 Lek Pharmaceuticals D.D. Peg-based dendron and process for producing the same
CN106906359B (zh) 2015-12-22 2018-12-11 理查德.亨威克 从硅酸盐矿物收取锂
CN110446499A (zh) 2017-03-20 2019-11-12 豪夫迈·罗氏有限公司 一种体外糖基工程化红细胞生成刺激蛋白的方法
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US439780A (en) * 1890-11-04 Method of and apparatus for casting ingots
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US4303650A (en) * 1979-10-09 1981-12-01 Ajinomoto Co., Inc. Process for production of erythropoietin
US4377513A (en) * 1980-08-25 1983-03-22 Ken Hayashibara Process for the production of human erythropoietin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5455790A (en) * 1977-10-05 1979-05-04 Tomoyuki Tajima Production of erythropoetin
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
JPS6043395A (ja) * 1983-08-19 1985-03-07 Sumitomo Chem Co Ltd エリスロポエチンの製造法
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IT1185503B (it) * 1984-01-11 1987-11-12 Univ New York Cloni di odna di eritropietina umana
JPS60215632A (ja) * 1984-04-12 1985-10-29 Japan Found Cancer エリスロポエチンの製造法
US4732889A (en) * 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
JPH062070B2 (ja) * 1988-07-06 1994-01-12 農林水産省食品総合研究所長 ▲ｏ下−▼アシルアミノ酸の製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US439780A (en) * 1890-11-04 Method of and apparatus for casting ingots
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US4303650A (en) * 1979-10-09 1981-12-01 Ajinomoto Co., Inc. Process for production of erythropoietin
US4377513A (en) * 1980-08-25 1983-03-22 Ken Hayashibara Process for the production of human erythropoietin

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Alan R. Liss, Inc. New York (1980 *
Carnot et al., Compt. Rend. 143:384, 1966; *
Espada et al., Biochem. Med., 3:475, 1970; *
Fischer, Pharm. Rev., 24:459, 1972; *
Goldwasser, Control Cellular, Dif. Develop. Part. A, p. 487-494; *
Gordon, Vitam. Horm. (N.Y.), 31:105, 1973; *
Guyton, Textbook of medical Phisiology, W. B. Saunders Co, Filadelfia, p. 56 -60, 1976; *
White et al., Rec. Progr. Horm. Res., 16-219, 1960; *

Also Published As

Publication number Publication date
NO863050L (no) 1986-07-28
DK368786A (da) 1986-08-01
LV10505A (lv) 1995-02-20
CZ281756B6 (cs) 1997-01-15
DK175826B1 (da) 2005-03-14
DK172953B1 (da) 1999-10-18
EP0411678B1 (en) 1992-01-08
HK105693A (en) 1993-10-15
FI19992064A (fi) 1999-09-27
LV10507A (lv) 1995-02-20
DK173254B1 (da) 2000-05-22
DK199901147A (da) 1999-08-20
JPH01257480A (ja) 1989-10-13
ES8800049A1 (es) 1987-10-16
EP0411678A1 (en) 1991-02-06
CZ287620B6 (cs) 2001-01-17
AU621535B2 (en) 1992-03-19
MD1639B2 (ro) 2001-03-31
UA44882C2 (uk) 2002-03-15
EP0411678B2 (en) 2000-01-12
ES549539A0 (es) 1987-10-16
GR852890B (ro) 1986-04-03
AU5313486A (en) 1986-07-01
ATE71408T1 (de) 1992-01-15
FI863044A0 (fi) 1986-07-24
JPH07184681A (ja) 1995-07-25
WO1986003520A1 (en) 1986-06-19
DE3582732D1 (de) 1991-06-06
PT81590A (en) 1986-01-01
IL77081A0 (en) 1986-04-29
EP0205564A4 (en) 1987-12-14
GEP19970775B (en) 1997-01-27
FI863044A (fi) 1986-07-24
DE3585161D1 (de) 1992-02-20
KR870700099A (ko) 1987-02-28
PL157926B1 (pl) 1992-07-31
PL256589A1 (en) 1986-10-21
EP0205564A1 (en) 1986-12-30
KR890001011B1 (en) 1989-04-18
SK279765B6 (sk) 1999-03-12
NO863050D0 (no) 1986-07-28
FI104261B1 (fi) 1999-12-15
FI105347B (fi) 2000-07-31
LV10507B (lv) 1996-06-20
FI104261B (fi) 1999-12-15
IL77081A (en) 1999-10-28
JPH02104284A (ja) 1990-04-17
EP0205564B1 (en) 1991-05-02
SK880485A3 (en) 1999-03-10
HUT40706A (en) 1987-01-28
SK168799A3 (en) 2001-08-06
PL154180B1 (en) 1991-07-31
HU216079B (hu) 1999-04-28
CA1341502C (en) 2006-03-21
PT81590B (pt) 1987-10-20
NO304469B1 (no) 1998-12-21
CZ880485A3 (en) 1996-08-14
EP0205564B2 (en) 2000-06-21
DE411678T1 (de) 1991-10-17
DK200000527A (da) 2000-03-29
DK368786D0 (da) 1986-08-01
DK173293B1 (da) 2000-06-13
JPH02442A (ja) 1990-01-05
HK105593A (en) 1993-10-15
ATE63137T1 (de) 1991-05-15
LV10505B (en) 1996-04-20
DK95197A (da) 1997-08-20
CZ286557B6 (cs) 2000-05-17
JPH0655144B2 (ja) 1994-07-27
CZ127496A3 (cs) 2000-02-16
MD940371A (ro) 1996-06-28
SK281799B6 (sk) 2001-08-06

Similar Documents

Publication Publication Date Title
MD1639C2 (ro) ADN sau fragmentele lui ce codifică eritropoietina umană, vectori, celule-gazdă sau linii celulare, ADNc sau fragmentele lui ce codifică eritropoietina umană, eritropoietină recombinantă umană, procedee de obţinere a eritropoietinei umane şi eritropoietinei recombinante umane, compoziţie farmaceutică şi procedeu de obţinere a ei
FR2681786B1 (ro)
DE69133459D1 (de) Methoden für die ex-vivo replikation und stabile genetische transformation von menschlichen stamm-zellen
IT1206311B (it) Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.
ES8401777A1 (es) Procedimiento para producir un polipeptido.
IL200005A (en) METHOD FOR THE PRODUCTION OF ALPH 2, 6 - GALACTOSIDES AND HUMAN CYLILE EXTRACTED
BR9712348A (pt) molécula de polinucleotídeo isolada, vetor de expressão, célula cultivada em que foi introduzido um vetor de expressão, processo para produzir um polipeptídeo homólogo de fgf, polipeptídeo homólogo de fgf isolado,composição farmacêutica, anticorpo, processos para estimular ex vivo células progenitoras de miócitos, e, paraliberar um agente ou droga seletivamente para o tecido do coração.
KR890701607A (ko) 섬유아세포 성장 인자의 유사체
WO1991004316A3 (en) Ciliary neurotrophic factor
IL74947A (en) Analogs of human gamma interferon having the partial sequence of human gamma interferon and genetic engineering process for the preparation thereof
HU903961D0 (en) Process for producing 11-beta-aryl-4-oestrenes and pharmaceutical preparatives containing these compounds
HUT56884A (en) Process for producing protein having urate oxidase activity, gene coding for it, expression vector, microorganisms and transformed cells
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
KR920004570A (ko) 사람 mk 단백질을 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, mk단백질의 생산 방법 및 사용방법
IL88034A0 (en) Mutant acidic fibroblast growth factor,its preparation and pharmaceutical compositions containing it
ATE139568T1 (de) Achromobacter-protease-i-gen sowie genprodukt
EP0218652B1 (en) A dna sequence
HUP9800520A2 (hu) Génexpresszió emlős sejtekben
DE3567213D1 (en) Erythromycin a salt with mucosecretolytic and fluidizing activity, a process for its preparation and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
PD99 Pending application
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MK4A Patent for invention expired